Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2022 17:41 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
February 14, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

Cidara intends to initiate the Phase 1 trial in Q1 2022 Drug-Fc conjugate (DFC) CD388 leverages Cidara’s Cloudbreak® platform and has the potential to offer significant advantages over current flu...
January 06, 2022 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...
December 14, 2021 07:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December...
November 22, 2021 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutive Year

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
November 10, 2021 16:05 ET | Source: Cidara Therapeutics, Inc.

Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
October 13, 2021 16:01 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
October 08, 2021 09:12 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
October 07, 2021 16:01 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for...
October 01, 2021 16:11 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for...